Montserrat E - Search Results

1

Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.

Cervantes F, Reverter JC, Montserrat E, Rozman C. Cervantes F, et al. Among authors: montserrat e. Cancer Treat Rep. 1986 May;70(5):665-7. Cancer Treat Rep. 1986. PMID: 3708614

2

Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease.

Villamor N, Reverter JC, Martí JM, Montserrat E, Rozman C. Villamor N, et al. Among authors: montserrat e. Eur J Haematol. 1991 Jan;46(1):38-41. doi: 10.1111/j.1600-0609.1991.tb00511.x. Eur J Haematol. 1991. PMID: 1988305

3

[Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients].

Cervantes F, Reverter JC, Bladé J, Montserrat E, Rozman C. Cervantes F, et al. Among authors: montserrat e. Sangre (Barc). 1988 Jun;33(3):184-7. Sangre (Barc). 1988. PMID: 2459787 Spanish. No abstract available.

4

Non-Hodgkin's lymphoma of unfavourable histology: a multivariate analysis of factors predicting the response to CHOP.

Pereira A, Cervantes F, Montserrat E, Llebaria C, Rozman C. Pereira A, et al. Among authors: montserrat e. Hematol Oncol. 1987 Jul-Sep;5(3):203-11. doi: 10.1002/hon.2900050307. Hematol Oncol. 1987. PMID: 3653858

5

Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP).

Bladé J, Rozman C, Montserrat E, Cervantes F, Feliu E, Grañena A, Marín P, Nomdedeu B. Bladé J, et al. Among authors: montserrat e. Eur J Cancer Clin Oncol. 1986 Oct;22(10):1193-7. doi: 10.1016/0277-5379(86)90320-2. Eur J Cancer Clin Oncol. 1986. PMID: 3816912

6

Treatment of blast crisis of chronic myelogenous leukemia with vincristine, prednisone, and cytarabine.

Cervantes F, Rozman C, Bladé J, Montserrat E, Grañena A. Cervantes F, et al. Among authors: montserrat e. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):923-4. Cancer Treat Rep. 1985. PMID: 3860299 No abstract available.

7

Etoposide in the treatment of multifocal eosinophilic granuloma.

Urbano-Márquez A, Estruch R, Fernandez-Huerta JM, Montserrat E, Rozman C. Urbano-Márquez A, et al. Among authors: montserrat e. Cancer Treat Rep. 1985 Feb;69(2):238-9. Cancer Treat Rep. 1985. PMID: 3971395 No abstract available.

8

[Treatment of Hodgkin's disease with ABVD].

Montserrat E, Carreras E, Rozman C, Olivé T, Bladé J, Cervantes F, Feliu E, Gardella S, Grañena A, Marín P, et al. Montserrat E, et al. Med Clin (Barc). 1984 Dec 1;83(18):739-41. Med Clin (Barc). 1984. PMID: 6084157 Spanish. No abstract available.

9

Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients.

Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C. Bladé J, et al. Among authors: montserrat e. Br J Haematol. 1994 Sep;88(1):117-21. doi: 10.1111/j.1365-2141.1994.tb04986.x. Br J Haematol. 1994. PMID: 7803233

10

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Montoto S, et al. Among authors: montserrat e. Cancer. 2000 May 1;88(9):2142-8. Cancer. 2000. PMID: 10813727

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

611 results

Search Page